CCND1 and prostate carcinoma: In our combined cohort, we observed recurrent tandem duplication events with breakpoints located in the flanking gene regions of several known prostate cancer oncogenes, including AR (35.7%), FOXA1 (16.8%), MYC (16.8%), and CCND1 (14.0%), consistent with frequencies that have been previously reported by us and others (10, 13, 15) (Figure 1C).